Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer

Part of paid clinical trials in La Jolla, California.

Sponsor
University of California, San Diego
Study ID
NCT02454140
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SBRT — RADIATION
    Fixed five-fraction stereotactic radiotherapy

Study Details

This study is to determine the maximum tolerated dose (MTD) of five fraction stereotactic radiotherapy (SBRT) in pancreatic cancer.

Key Dates

Start date
Jun 20, 2014
Status verified
Aug 2025
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022

Study Design

Enrollment
30 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Cohort 1
    SBRT 40 Gy in 5 fractions
  • Experimental: Cohort 2
    SBRT 45 Gy in 5 fractions (starting dose level)
  • Experimental: Cohort 3
    SBRT 50 Gy in 5 fractions
  • Experimental: Cohort 4
    SBRT 55 Gy in 5 fractions
  • Experimental: Cohort 5
    SBRT 60 Gy in 5 fractions

Primary Outcome Measure

Maximum Tolerated Dose [ Time Frame: From date of randomization to observed dose limiting toxicity (DLT) in 20% of patients assessed up to 3 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCSD Moores Cancer CenterLa JollaCalifornia92093-

Find similar trials in La Jolla, CA

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
UCSD Moores Cancer Center· La Jolla, CA

Related Studies